Amicus Therapeutics, Inc. Stock London S.E.
Stocks
0HF9
US03152W1099
Biotechnology & Medical Research
| Market Cap | 4.55B 3.94B 3.72B 3.38B 6.33B 436B 6.38B 44.43B 17.12B 221B 17.09B 16.71B 703B | P/E 2024 |
-51.1x | P/E 2025 | -162x |
|---|---|---|---|---|---|
| Enterprise Value | 4.7B 4.07B 3.84B 3.49B 6.54B 450B 6.59B 45.89B 17.68B 228B 17.65B 17.26B 726B | EV / Sales 2024 |
5.69x | EV / Sales 2025 | 7.18x |
| Free-Float |
99.31% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Amicus Therapeutics, Inc.
| 1 day | +17.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
George Davis
PSD | President | 55 | 27/04/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +17.93% | +18.15% | - | - | 4.55B | |
| +0.56% | -4.71% | -2.38% | +9.18% | 45.48B | |
| +0.13% | -1.96% | +339.97% | +524.47% | 43.68B | |
| +1.77% | +2.82% | +43.32% | +25.15% | 43.09B | |
| +2.38% | +1.17% | +7.02% | +79.14% | 39.4B | |
| +0.34% | -4.94% | +9.34% | +40.23% | 31.91B | |
| -0.61% | -2.47% | - | - | 17.31B | |
| +1.25% | +0.67% | +19.83% | +112.42% | 16.4B | |
| +2.07% | +0.78% | +14.39% | +30.91% | 14.24B | |
| -1.60% | -2.65% | +79.53% | +31.56% | 13.28B | |
| Average | +2.47% | -2.97% | +63.88% | +106.63% | 29.42B | |
| Weighted average by Cap. | +1.23% | -3.26% | +75.84% | +127.34% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 528M 458M 432M 392M 735M 50.63B 741M 5.16B 1.99B 25.69B 1.98B 1.94B 81.66B | 634M 550M 519M 470M 883M 60.79B 889M 6.19B 2.39B 30.84B 2.38B 2.33B 98.04B |
| Net income | -56.11M -48.62M -45.88M -41.62M -78.08M -5.38B -78.64M -548M -211M -2.73B -211M -206M -8.67B | -27.11M -23.49M -22.17M -20.11M -37.73M -2.6B -38M -265M -102M -1.32B -102M -99.58M -4.19B |
| Net Debt | 194M 168M 158M 144M 270M 18.57B 272M 1.89B 729M 9.42B 728M 711M 29.94B | 149M 129M 122M 110M 207M 14.26B 209M 1.45B 560M 7.24B 559M 547M 23.01B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
